newsfilter
← Latest News
GlobeNewswire·

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed